{"title":"COVID-19对持续性和慢性成人ITP患者血小板计数的影响：一项在中国的真实世界研究","authors":"Yujiao Zhang, Lei Yang, Zhongping Xu, Xin Zhou","doi":"10.1002/jha2.70025","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Objective</h3>\n \n <p>While coronavirus disease 2019 (COVID-19)-associated thrombocytopenia is well-documented, its effects on immune thrombocytopenia (ITP) patients remain unclear. This study aimed to investigate the impact of COVID-19 infection on platelet (PLT) dynamics in chronic ITP patients.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>This retrospective study analyzed 21 persistent and chronic ITP patients before and after mild COVID-19 infection during China's December 2022 reopening, comparing platelet parameter changes with a focus on clinical characteristics of thrombopoietin receptor agonist (TPO-RA) treated patients.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>TPO-RA treated patients demonstrated transient platelet surges peaking at 1 week postinfection, returning to baseline within 2–3 weeks, contrasting sharply with thrombocytopenia patterns in non-ITP populations. This suggests synergistic effects between virus-induced inflammatory cytokines and TPO-RA may drive transient megakaryopoiesis.</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>These findings underscore infection-related PLT fluctuations in ITP, necessitating monitoring for thrombotic and bleeding risks and TPO-RA dose optimization during infections.</p>\n </section>\n \n <section>\n \n <h3> Trial Registration</h3>\n \n <p>The authors have confirmed clinical trial registration is not needed for this submission</p>\n </section>\n </div>","PeriodicalId":72883,"journal":{"name":"EJHaem","volume":"6 2","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2025-03-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jha2.70025","citationCount":"0","resultStr":"{\"title\":\"The Effect of COVID-19 on Platelet Counts in Persistent and Chronic Adult ITP Patients: A Real-World Study in China\",\"authors\":\"Yujiao Zhang, Lei Yang, Zhongping Xu, Xin Zhou\",\"doi\":\"10.1002/jha2.70025\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n \\n \\n <section>\\n \\n <h3> Objective</h3>\\n \\n <p>While coronavirus disease 2019 (COVID-19)-associated thrombocytopenia is well-documented, its effects on immune thrombocytopenia (ITP) patients remain unclear. This study aimed to investigate the impact of COVID-19 infection on platelet (PLT) dynamics in chronic ITP patients.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Methods</h3>\\n \\n <p>This retrospective study analyzed 21 persistent and chronic ITP patients before and after mild COVID-19 infection during China's December 2022 reopening, comparing platelet parameter changes with a focus on clinical characteristics of thrombopoietin receptor agonist (TPO-RA) treated patients.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Results</h3>\\n \\n <p>TPO-RA treated patients demonstrated transient platelet surges peaking at 1 week postinfection, returning to baseline within 2–3 weeks, contrasting sharply with thrombocytopenia patterns in non-ITP populations. This suggests synergistic effects between virus-induced inflammatory cytokines and TPO-RA may drive transient megakaryopoiesis.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Conclusion</h3>\\n \\n <p>These findings underscore infection-related PLT fluctuations in ITP, necessitating monitoring for thrombotic and bleeding risks and TPO-RA dose optimization during infections.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Trial Registration</h3>\\n \\n <p>The authors have confirmed clinical trial registration is not needed for this submission</p>\\n </section>\\n </div>\",\"PeriodicalId\":72883,\"journal\":{\"name\":\"EJHaem\",\"volume\":\"6 2\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-03-29\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jha2.70025\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"EJHaem\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/jha2.70025\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"EJHaem","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/jha2.70025","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
The Effect of COVID-19 on Platelet Counts in Persistent and Chronic Adult ITP Patients: A Real-World Study in China
Objective
While coronavirus disease 2019 (COVID-19)-associated thrombocytopenia is well-documented, its effects on immune thrombocytopenia (ITP) patients remain unclear. This study aimed to investigate the impact of COVID-19 infection on platelet (PLT) dynamics in chronic ITP patients.
Methods
This retrospective study analyzed 21 persistent and chronic ITP patients before and after mild COVID-19 infection during China's December 2022 reopening, comparing platelet parameter changes with a focus on clinical characteristics of thrombopoietin receptor agonist (TPO-RA) treated patients.
Results
TPO-RA treated patients demonstrated transient platelet surges peaking at 1 week postinfection, returning to baseline within 2–3 weeks, contrasting sharply with thrombocytopenia patterns in non-ITP populations. This suggests synergistic effects between virus-induced inflammatory cytokines and TPO-RA may drive transient megakaryopoiesis.
Conclusion
These findings underscore infection-related PLT fluctuations in ITP, necessitating monitoring for thrombotic and bleeding risks and TPO-RA dose optimization during infections.
Trial Registration
The authors have confirmed clinical trial registration is not needed for this submission
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
